Arcturus Therapeutics (ARCT) stock took a beating on Wednesday after the RNA medicines company provided interim results from a Phase 2 clinical trial. This trial covers ARCT-032, a potential inhaled mRNA therapy for patients with cystic fibrosis. This is a genetic disorder that affects the body’s mucus-producing glands, resulting in the production of thick, sticky mucus that clogs the airways, digestive tract, and other organs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Arcturus Therapeutics noted that the clinical trial hasn’t demonstrated meaningful improvement in FEV values. However, the company noted that there were improvements after the study ended. This suggests ARCT-032 could have an impact over the long term following daily treatments. The company has decided to conduct a 12-week study in the first half of 2026 to explore this possibility.
Dr. Harm Tiddens, Professor Emeritus of Pediatric Pulmonology at Erasmus Medical Center, said, “Seeing a trend towards a reduction in mucus plugs and volume after only 28 days of treatment suggests biological activity. Mucus plug reduction can be followed with longer-term lung function improvements over multi-month treatment durations. These findings suggest that ARCT-032 may be addressing the underlying pathology of cystic fibrosis in a meaningful way.”
Arcturus Therapeutics Stock Movement Today
Arcturus Therapeutics stock was down 54.66% in pre-market trading on Wednesday, following a 7.67% rally yesterday. The shares have increased 36.48% year-to-date and 15.8% over the past 12 months. Today’s news came with heavy trading, as some 2.3 million shares changed hands, compared to a three-month daily average of about 830,000 units.
Is Arcturus Therapeutics Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Arcturus Therapeutics is Strong Buy, based on seven Buy ratings over the past three months. With that comes an average ARCT stock price target of $52.40, representing a potential 126.25% upside for the shares.
